‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
4 sourcesUpdated 1m ago

Coverage across the spectrum
How we rate outletsLeft 25% · 1Center 75% · 3Right 0% · 0
The story so far
- New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent.
- First-of-Its-Kind Vaccine Ushers in New Hope for Cancer Patients.
- The ESMO presentation everyone’s been waiting for.
Summarised from the linked sources. Methodology
Who's reporting it
- FBFierce BiotechCenter
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
- statnews.comSstatnews.comCenter
The ESMO presentation everyone’s been waiting for
- The New York TimesTN
The New York TimesLeftFirst-of-Its-Kind Vaccine Ushers in New Hope for Cancer Patients
- WWired2FishCenter
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Reader Discussion
Loading comments…





